newsfilter
← Latest News
GlobeNewswire·

RZLT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

  • Faruqi & Faruqi, LLP is investigating potential securities claims against Rezolute, Inc. (NASDAQ: RZLT).
  • Rezolute shares collapsed approximately 85–90% on December 11, 2025, dropping from near $10.94 to an intraday low near $0.90.
  • The stock decline followed disappointing Phase 3 sunRIZE clinical trial results for the drug candidate ersodetug, which failed to meet primary & key secondary endpoints for treating congenital hyperinsulinism.
  • The highest dose of ersodetug showed reductions in hypoglycemia events that were not statistically significant versus placebo.
  • Trading in RZLT was halted under Nasdaq's volatility controls during the sharp intraday drop.
  • Investors who suffered significant losses are encouraged to contact partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss legal options.
  • Additional information regarding the investigation is available at www.faruqilaw.com/RZLT.